Microglia-Mediated Neurovascular Unit Dysfunction in Alzheimer's Disease
Wenhao Huang1, Qing Xia1,2, Feifei Zheng1
1Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang Province, China.
Journal of Alzheimer'S Disease : JAD
|January 23, 2023
Summary
Microglia contribute to Alzheimer's disease (AD) pathology by disrupting the neurovascular unit (NVU). This review explores microglia-driven NVU dysfunction in AD and discusses therapeutic strategies targeting microglia and the NVU.
Area of Science:
- Neuroscience
- Pathology
- Cell Biology
Background:
- The neurovascular unit (NVU) is crucial for central nervous system homeostasis.
- Alzheimer's disease (AD) involves pathological changes within the NVU.
- Microglia play a significant role in NVU dysfunction during AD progression.
Purpose of the Study:
- To review the mechanisms of microglia-mediated NVU dysfunction in Alzheimer's disease.
- To discuss current therapeutic strategies for restoring microglia and NVU function in AD.
- To highlight the future research focus on pericyte roles in microglia-mediated NVU dysfunction.
Main Methods:
- Literature review of mechanisms underlying microglia-mediated NVU dysfunction in AD.
- Analysis of existing therapeutic advancements targeting microglia and NVU in AD.
- Synthesis of current understanding and future predictions regarding pericyte involvement.
Main Results:
- Microglia induce blood-brain barrier breakdown via neuroinflammation, immune cell infiltration, and oxidative stress.
- Microglia mediate neurovascular uncoupling through neuronal mitochondrial dysfunction, cerebral vessel abnormalities, and pericyte loss.
- Microglia-induced dysfunction of astrocytes and pericytes further impairs NVU integrity in AD.
Conclusions:
- Microglia are key drivers of NVU impairment in Alzheimer's disease.
- Therapeutic strategies aimed at modulating microglial activity and restoring NVU function show promise for AD treatment.
- The role of pericytes in microglia-mediated NVU dysfunction represents a critical area for future research in AD.
Related Concept Videos
Alzheimer's Disease: Overview
597
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
597
Alzheimer's Disease: Treatment
238
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
238


